
Dow-Mu Koh

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1271037/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Diffusion-Weighted MRI in the Body: Applications and Challenges in Oncology. American Journal of Roentgenology, 2007, 188, 1622-1635.	2.2	1,730
2	Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. Science, 2018, 359, 920-926.	12.6	1,199
3	Imaging biomarker roadmap for cancer studies. Nature Reviews Clinical Oncology, 2017, 14, 169-186.	27.6	792
4	Intravoxel Incoherent Motion in Body Diffusion-Weighted MRI: Reality and Challenges. American Journal of Roentgenology, 2011, 196, 1351-1361.	2.2	469
5	Predicting Response of Colorectal Hepatic Metastasis: Value of Pretreatment Apparent Diffusion Coefficients. American Journal of Roentgenology, 2007, 188, 1001-1008.	2.2	324
6	Body diffusion kurtosis imaging: Basic principles, applications, and considerations for clinical practice. Journal of Magnetic Resonance Imaging, 2015, 42, 1190-1202.	3.4	274
7	Rectal Cancer: Mesorectal Lymph Nodes at MR Imaging with USPIO versus Histopathologic Findings—Initial Observations. Radiology, 2004, 231, 91-99.	7.3	244
8	METastasis Reporting and Data System for Prostate Cancer: Practical Guidelines for Acquisition, Interpretation, and Reporting of Whole-body Magnetic Resonance Imaging-based Evaluations of Multiorgan Involvement in Advanced Prostate Cancer. European Urology, 2017, 71, 81-92.	1.9	230
9	Practical Aspects of Assessing Tumors Using Clinical Diffusion-weighted Imaging in the Body. Magnetic Resonance in Medical Sciences, 2007, 6, 211-224.	2.0	191
10	Whole-Body Diffusion-Weighted MRI: Tips, Tricks, and Pitfalls. American Journal of Roentgenology, 2012, 199, 252-262.	2.2	158
11	Reproducibility and changes in the apparent diffusion coefficients of solid tumours treated with combretastatin A4 phosphate and bevacizumab in a two-centre phase I clinical trial. European Radiology, 2009, 19, 2728-2738.	4.5	151
12	Diffusionâ€weighted imaging outside the brain: Consensus statement from an ISMRMâ€sponsored workshop. Journal of Magnetic Resonance Imaging, 2016, 44, 521-540.	3.4	146
13	Radiomics in Oncology: A Practical Guide. Radiographics, 2021, 41, 1717-1732.	3.3	139
14	Evaluating Mesorectal Lymph Nodes in Rectal Cancer Before and After Neoadjuvant Chemoradiation Using Thin-Section T2-Weighted Magnetic Resonance Imaging. International Journal of Radiation Oncology Biology Physics, 2008, 71, 456-461.	0.8	126
15	Assessment of Treatment Response by Total Tumor Volume and Global Apparent Diffusion Coefficient Using Diffusion-Weighted MRI in Patients with Metastatic Bone Disease: A Feasibility Study. PLoS ONE, 2014, 9, e91779.	2.5	104
16	Whole-Body MRI: Current Applications in Oncology. American Journal of Roentgenology, 2017, 209, W336-W349.	2.2	89
17	Diffusion-weighted Imaging as a Treatment Response Biomarker for Evaluating Bone Metastases in Prostate Cancer: A Pilot Study. Radiology, 2017, 283, 168-177.	7.3	81
18	Diagnostic Accuracy of Nodal Enhancement Pattern of Rectal Cancer at MRI Enhanced With Ultrasmall Superparamagnetic Iron Oxide: Findings in Pathologically Matched Mesorectal Lymph Nodes. American Journal of Roentgenology, 2010, 194, W505-W513.	2.2	75

#	Article	IF	CITATIONS
19	UK quantitative WB-DWI technical workgroup: consensus meeting recommendations on optimisation, quality control, processing and analysis of quantitative whole-body diffusion-weighted imaging for cancer. British Journal of Radiology, 2018, 91, 20170577.	2.2	70
20	Functional imaging and circulating biomarkers of response to regorafenib in treatment-refractory metastatic colorectal cancer patients in a prospective phase II study. Gut, 2018, 67, 1484-1492.	12.1	59
21	Consensus report from the 8th International Forum for Liver Magnetic Resonance Imaging. European Radiology, 2020, 30, 370-382.	4.5	55
22	Baseline results from the UK SIGNIFY study: a whole-body MRI screening study in TP53 mutation carriers and matched controls. Familial Cancer, 2017, 16, 433-440.	1.9	52
23	Diagnostic accuracy of whole-body MRI versus standard imaging pathways for metastatic disease in newly diagnosed colorectal cancer: the prospective Streamline C trial. The Lancet Gastroenterology and Hepatology, 2019, 4, 529-537.	8.1	51
24	Diagnostic accuracy of whole-body MRI versus standard imaging pathways for metastatic disease in newly diagnosed non-small-cell lung cancer: the prospective Streamline L trial. Lancet Respiratory Medicine,the, 2019, 7, 523-532.	10.7	50
25	The Predictive Value of Early Assessment After 1 Cycle of Induction Chemotherapy with ¹⁸ F-FDG PET/CT and Diffusion-Weighted MRI for Response to Radical Chemoradiotherapy in Head and Neck Squamous Cell Carcinoma. Journal of Nuclear Medicine, 2016, 57, 1843-1850.	5.0	49
26	Imaging Diagnosis and Follow-up of Advanced Prostate Cancer: Clinical Perspectives and State of the Art. Radiology, 2019, 292, 273-286.	7.3	46
27	New Horizons in Oncologic Imaging. New England Journal of Medicine, 2003, 348, 2487-2488.	27.0	45
28	lmaging of Tumor Angiogenesis for Radiologists—Part 1: Biological and Technical Basis. Current Problems in Diagnostic Radiology, 2015, 44, 407-424.	1.4	45
29	Extracranial Soft-Tissue Tumors: Repeatability of Apparent Diffusion Coefficient Estimates from Diffusion-weighted MR Imaging. Radiology, 2017, 284, 88-99.	7.3	45
30	Liver-specific agents for contrast-enhanced MRI: role in oncological imaging. Cancer Imaging, 2013, 13, 567-579.	2.8	44
31	Inter- and Intra-Observer Repeatability of Quantitative Whole-Body, Diffusion-Weighted Imaging (WBDWI) in Metastatic Bone Disease. PLoS ONE, 2016, 11, e0153840.	2.5	40
32	Repeatability of derived parameters from histograms following non-Gaussian diffusion modelling of diffusion-weighted imaging in a paediatric oncological cohort. European Radiology, 2017, 27, 345-353.	4.5	40
33	Intimate partner violence crisis in the COVID-19 pandemic: how can radiologists make a difference?. European Radiology, 2020, 30, 6933-6936.	4.5	40
34	Multiparametric Magnetic Resonance Imaging of Prostate Cancer Bone Disease. Investigative Radiology, 2018, 53, 96-102.	6.2	36
35	The Relationship between MR Demonstration of Extramural Venous Invasion and Nodal Disease in Rectal Cancer. Clinical Medicine Oncology, 2008, 2, CMO.S370.	0.3	35
36	Evaluating the diagnostic sensitivity of computed diffusionâ€weighted MR imaging in the detection of breast cancer. Journal of Magnetic Resonance Imaging, 2016, 44, 130-137.	3.4	35

#	Article	IF	CITATIONS
37	Rapid development of image analysis research tools: Bridging the gap between researcher and clinician with pyOsiriX. Computers in Biology and Medicine, 2016, 69, 203-212.	7.0	34
38	Whole-body MRI compared with standard pathways for staging metastatic disease in lung and colorectal cancer: the Streamline diagnostic accuracy studies. Health Technology Assessment, 2019, 23, 1-270.	2.8	34
39	Evaluation of Clinically Translatable MR Imaging Biomarkers of Therapeutic Response in the TH-MYCNTransgenic Mouse Model of Neuroblastoma. Radiology, 2013, 266, 130-140.	7.3	33
40	Pseudoprogression in children, adolescents and young adults with non-brainstem high grade glioma and diffuse intrinsic pontine glioma. Journal of Neuro-Oncology, 2016, 129, 109-121.	2.9	30
41	MRI-based Assessment of 3D Intrafractional Motion of Head and Neck Cancer for RadiationÂTherapy. International Journal of Radiation Oncology Biology Physics, 2018, 100, 306-316.	0.8	28
42	Whole-body magnetic resonance imaging (WB-MRI) for cancer screening in asymptomatic subjects of the general population: review and recommendations. Cancer Imaging, 2020, 20, 34.	2.8	27
43	Oncologically Relevant Findings Reporting and Data System (ONCO-RADS): Guidelines for the Acquisition, Interpretation, and Reporting of Whole-Body MRI for Cancer Screening. Radiology, 2021, 299, 494-507.	7.3	26
44	Response evaluation in mesothelioma: Beyond RECIST. Lung Cancer, 2015, 90, 433-441.	2.0	25
45	Intravoxel incoherent imaging of renal fibrosis induced in a murine model of unilateral ureteral obstruction. Magnetic Resonance Imaging, 2015, 33, 1324-1328.	1.8	25
46	A clinicalâ€radiomic model for improved prognostication of surgical candidates with colorectal liver metastases. Journal of Surgical Oncology, 2020, 121, 357-364.	1.7	24
47	Comparison of Whole-Body MRI, CT, and Bone Scintigraphy for Response Evaluation of Cancer Therapeutics in Metastatic Breast Cancer to Bone. Radiology, 2020, 297, 622-629.	7.3	24
48	Diffusion-weighted MR neurography for the assessment of brachial plexopathy in oncological practice. Cancer Imaging, 2015, 15, 6.	2.8	23
49	Texture analysis of apparent diffusion coefficient maps for treatment response assessment in prostate cancer bone metastases—A pilot study. European Journal of Radiology, 2018, 101, 184-190.	2.6	23
50	Demonstration of the reproducibility of free-breathing diffusion-weighted MRI and dynamic contrast enhanced MRI in children with solid tumours: a pilot study. European Radiology, 2015, 25, 2641-2650.	4.5	22
51	Prospective Evaluation of Whole-Body MRI versus FDG PET/CT for Lesion Detection in Participants with Myeloma. Radiology Imaging Cancer, 2021, 3, e210048.	1.6	22
52	Reduction in respiratory motion artefacts on gadoxetate-enhanced MRI after training technicians to apply a simple and more patient-adapted breathing command. European Radiology, 2016, 26, 2714-2722.	4.5	21
53	Blood transfusion during radical chemo-radiotherapy does not reduce tumour hypoxia in squamous cell cancer of the head and neck. British Journal of Cancer, 2017, 116, 28-35.	6.4	20
54	Quantitative Whole-Body Diffusion-Weighted MR Imaging. Magnetic Resonance Imaging Clinics of North America, 2018, 26, 479-494.	1.1	19

#	Article	IF	CITATIONS
55	Interobserver agreement of whole-body magnetic resonance imaging is superior to whole-body computed tomography for assessing disease burden in patients with multiple myeloma. European Radiology, 2020, 30, 320-327.	4.5	18
56	Rapid 4D-MRI reconstruction using a deep radial convolutional neural network: Dracula. Radiotherapy and Oncology, 2021, 159, 209-217.	0.6	18
57	Reduced Warburg Effect in Cancer Cells Undergoing Autophagy: Steady- State 1H-MRS and Real-Time Hyperpolarized 13C-MRS Studies. PLoS ONE, 2014, 9, e92645.	2.5	17
58	Early Treatment Response in Non-Small Cell Lung Cancer Patients Using Diffusion-Weighted Imaging and Functional Diffusion Maps – A Feasibility Study. PLoS ONE, 2014, 9, e108052.	2.5	17
59	Body Diffusion-weighted MR Imaging in Oncology. Magnetic Resonance Imaging Clinics of North America, 2016, 24, 31-44.	1.1	17
60	Intrinsic Susceptibility MRI Identifies Tumors with ALKF1174L Mutation in Genetically-Engineered Murine Models of High-Risk Neuroblastoma. PLoS ONE, 2014, 9, e92886.	2.5	16
61	Diagnostic Accuracy of Rim and Segmental MRI Enhancement of Colorectal Hepatic Metastasis After Administration of Mangafodipir Trisodium. American Journal of Roentgenology, 2007, 188, W154-W161.	2.2	15
62	Nanoparticles in rectal cancer imaging. Cancer Biomarkers, 2009, 5, 89-98.	1.7	15
63	lmaging of Tumor Angiogenesis for Radiologists—Part 2: Clinical Utility. Current Problems in Diagnostic Radiology, 2015, 44, 425-436.	1.4	15
64	Psychosocial effects of whole-body MRI screening in adult high-risk pathogenic <i>TP53</i> mutation carriers: a case-controlled study (SIGNIFY). Journal of Medical Genetics, 2020, 57, 226-236.	3.2	15
65	Noninvasive MRI Native T1 Mapping Detects Response to <i>MYCN</i> -targeted Therapies in the Th- <i>MYCN</i> Model of Neuroblastoma. Cancer Research, 2020, 80, 3424-3435.	0.9	15
66	Combination of chemical suppression techniques for dual suppression of fat and silicone at diffusion-weighted MR imaging in women with breast implants. European Radiology, 2012, 22, 2648-2653.	4.5	14
67	Comparison of a coaxial versus non-coaxial liver biopsy technique in an oncological setting: diagnostic yield, complications and seeding risk. European Radiology, 2020, 30, 6702-6708.	4.5	14
68	Addressing intimate partner violence during the COVID-19 pandemic and beyond: how radiologists can make a difference. European Radiology, 2021, 31, 2126-2131.	4.5	14
69	MRI texture feature repeatability and image acquisition factor robustness, a phantom study and in silico study. European Radiology Experimental, 2021, 5, 2.	3.4	14
70	Consensus report from the 9th International Forum for Liver Magnetic Resonance Imaging: applications of gadoxetic acid-enhanced imaging. European Radiology, 2021, 31, 5615-5628.	4.5	14
71	MRI Imaging of the Hemodynamic Vasculature of Neuroblastoma Predicts Response to Antiangiogenic Treatment. Cancer Research, 2019, 79, 2978-2991.	0.9	13
72	Using Deep Learning for MRI to Identify Responders to Chemoradiotherapy in Rectal Cancer. Radiology, 2020, 296, 65-66.	7.3	13

#	Article	IF	CITATIONS
73	Perfusion Imaging in Liver MRI. Magnetic Resonance Imaging Clinics of North America, 2014, 22, 417-432.	1.1	12
74	Diffusion-Weighted Imaging of the Male Pelvis. Radiologic Clinics of North America, 2012, 50, 1127-1144.	1.8	11
75	Serum albumin, total bilirubin, and patient age are independent confounders of hepatobiliary-phase gadoxetate parenchymal liver enhancement. European Radiology, 2019, 29, 5813-5822.	4.5	11
76	Diagnostic Accuracy of FEC-PET/CT, FDG-PET/CT, and Diffusion-Weighted MRI in Detection of Nodal Metastases in Surgically Treated Endometrial and Cervical Carcinoma. Clinical Cancer Research, 2021, 27, 6457-6466.	7.0	11
77	Functional Magnetic Resonance Imaging of the Liver: Parametric Assessments Beyond Morphology. Magnetic Resonance Imaging Clinics of North America, 2010, 18, 565-585.	1.1	10
78	Utility of preoperative ferumoxtran-10 MRI to evaluate retroperitoneal lymph node metastasis in advanced cervical cancer: Results of ACRIN 6671/GOG 0233. European Journal of Radiology Open, 2015, 2, 11-18.	1.6	10
79	Age dependence of spleen- and muscle-corrected hepatic signal enhancement on hepatobiliary phase gadoxetate MRI. European Radiology, 2016, 26, 1889-1894.	4.5	10
80	T 2 -adjusted computed diffusion-weighted imaging: A novel method to enhance tumour visualisation. Computers in Biology and Medicine, 2016, 79, 92-98.	7.0	9
81	Non-Mono-Exponential Analysis of Diffusion-Weighted Imaging for Treatment Monitoring in Prostate Cancer Bone Metastases. Scientific Reports, 2017, 7, 5809.	3.3	9
82	Contrast-Enhanced CT Density Predicts Response to Sunitinib Therapy in Metastatic Renal Cell Carcinoma Patients. Translational Oncology, 2017, 10, 679-685.	3.7	9
83	Considerations for artificial intelligence clinical impact in oncologic imaging: an AI4HI position paper. Insights Into Imaging, 2022, 13, 89.	3.4	9
84	Accelerating Whole-Body Diffusion-weighted MRI with Deep Learning–based Denoising Image Filters. Radiology: Artificial Intelligence, 2021, 3, e200279.	5.8	8
85	Multiparametric bone MRI can improve CT-guided bone biopsy target selection in cancer patients and increase diagnostic yield and feasibility of next-generation tumour sequencing. European Radiology, 2022, , 1.	4.5	8
86	A review on the added value of whole-body MRI in metastatic lobular breast cancer. European Radiology, 2022, 32, 6514-6525.	4.5	8
87	Pilot study on the detection of antiandrogen resistance using serial diffusionâ€weighted imaging of bone metastases in prostate cancer. Journal of Magnetic Resonance Imaging, 2016, 43, 1407-1416.	3.4	7
88	Post-radiotherapy apparent diffusion coefficient (ADC) in children and young adults with high-grade gliomas and diffuse intrinsic pontine gliomas. Pediatric Hematology and Oncology, 2019, 36, 103-112.	0.8	7
89	Modulation of renal oxygenation and perfusion in rat kidney monitored by quantitative diffusion and blood oxygen level dependent magnetic resonance imaging on a clinical 1.5T platform. BMC Nephrology, 2016, 17, 142.	1.8	6
90	Response Assessment in Paediatric Phase I Trials According to RECIST Guidelines: Survival Outcomes, Patterns of Progression and Relevance of Changes in Tumour Measurements. Pediatric Blood and Cancer, 2016, 63, 1400-1406.	1.5	6

#	Article	IF	CITATIONS
91	Characterizing Heterogeneity within Head and Neck Lesions Using Cluster Analysis of Multi-Parametric MRI Data. PLoS ONE, 2015, 10, e0138545.	2.5	6
92	Starting CT-guided robotic interventional oncology at a UK centre. British Journal of Radiology, 2022, 95, 20220217.	2.2	5
93	Transgender health and medicine – Are radiological devices prepared?. European Journal of Radiology, 2022, 151, 110320.	2.6	5
94	Diffusion-Weighted MR Imaging in Oncology. Current Radiology Reports, 2014, 2, 1.	1.4	4
95	Childhood extracranial neoplasms: the role of imaging in drug development and clinical trials. Pediatric Radiology, 2015, 45, 1600-1615.	2.0	4
96	DCE-MRI is more sensitive than IVIM-DWI for assessing anti-angiogenic treatment-induced changes in colorectal liver metastases. Cancer Imaging, 2021, 21, 67.	2.8	4
97	Critical questions in the imaging of colorectal hepatic metastases. Cancer Imaging, 2008, 8, S69-S78.	2.8	3
98	Liver-specific contrast agents. Cancer Imaging, 2012, 12, 363-364.	2.8	3
99	Whole-body diffusion-weighted MRI in lymphomaâ€"comparison of global apparent diffusion coefficient histogram parameters for differentiation of diseased nodes of lymphoma patients from normal lymph nodes of healthy individuals. Quantitative Imaging in Medicine and Surgery, 2021, 11, 3549-3561.	2.0	3
100	Feasibility and applicability of diffusion-weighted and dynamic contrast-enhanced magnetic resonance imaging in routine assessments of children with high-grade gliomas. Pediatric Blood and Cancer, 2017, 64, 279-283.	1.5	2
101	Would it be safe to have a dog in the MRI scanner before your own examination? A multicenter study to establish hygiene facts related to dogs and men. European Radiology, 2019, 29, 527-534.	4.5	2
102	Diagnostic Accuracy and Safety of Coaxial System in Oncology Patients Treated in a Specialist Cancer Center With Prospective Validation Within Clinical Trial Data. Frontiers in Oncology, 2020, 10, 1634.	2.8	2
103	New Advances in Magnetic Resonance Techniques in Abdomen and Pelvis. Magnetic Resonance Imaging Clinics of North America, 2020, 28, 433-445.	1.1	2
104	Prospective comparison of whole body MRI and FDG PET/CT for detection of multiple myeloma and correlation with markers of disease burden: Results of the iTIMM trial Journal of Clinical Oncology, 2021, 39, 8012-8012.	1.6	2
105	Competing Technology for PET/Computed Tomography. PET Clinics, 2013, 8, 259-277.	3.0	1
106	Early response to chemotherapy in malignant pleural mesothelioma assessed using diffusion-weighted MRI: Initial observations. JTO Clinical and Research Reports, 2021, 2, 100253.	1.1	0